<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40380042</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1568-5608</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>6</Issue><PubDate><Year>2025</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Inflammopharmacology</Title><ISOAbbreviation>Inflammopharmacology</ISOAbbreviation></Journal><ArticleTitle>Clinical study evaluating the efficacy and safety of Cilostazol as an adjuvant therapy to methotrexate on patients with rheumatoid arthritis.</ArticleTitle><Pagination><StartPage>3499</StartPage><EndPage>3508</EndPage><MedlinePgn>3499-3508</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10787-025-01782-2</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aims to assess the safety as well as effectiveness of Cilostazol as a complementary therapy to methotrexate among individuals with active rheumatoid arthritis.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">This study was a randomly allocated, double-blind, placebo-controlled parallel design involving 70 patients who were diagnosed with active rheumatoid arthritis. Participants were randomly assigned to two sets: the control group (n&#x2009;=&#x2009;35) which received methotrexate "MTX" (7.5&#xa0;mg IM weekly) plus placebo tablets twice daily and the Cilostazol group (n&#x2009;=&#x2009;35), which received the same MTX" dose plus Cilostazol 50&#xa0;mg twice daily&#xa0;for 3&#xa0;months. Patients were assessed to determine the serum levels of C-reactive protein (CRP) nuclear factor kappa B (NF-&#x3ba;B), hemoxygenase-1 (HO-1), and cyclic adenosine monophosphate (cAMP). Disease Activity Score (DAS28-CRP), Multidimensional Health Assessment Score (MDHAQ), and morning stiffness duration were also assessed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The Cilostazol group produced a significant improvement in cAMP level as compared to the control group (P&#x2009;=&#x2009;0.001). cAMP level showed a significant inverse correlation with DAS28-CRP (r&#x2009;=&#x2009;-0.336; P&#x2009;=&#x2009;0.004). However, Cilostazol group produced non-significant improvements in the serum levels of the other biological markers (CRP, NF-&#x3ba;B, and HO-1), DAS28-CRP score, MDHAQ score, and morning stiffness duration as compared to the control group (P&#x2009;&gt;&#x2009;0.05). The implication of Cilostazol for patients with rheumatoid arthritis was tolerable and safe.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The beneficial effect of Cilostazol on cAMP and the negative correlation between cAMP and DAS28-CRP could support its impact on the disease activity. Further research seems necessary to elucidate the mechanisms underlying the link between cAMP and disease activity.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">Clinical Trials.gov identifier: NCT05594680, The date of registration is: 30/10/2022.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Eldadamony</LastName><ForeName>Samar M</ForeName><Initials>SM</Initials><Identifier Source="ORCID">0009-0002-7202-6843</Identifier><AffiliationInfo><Affiliation>Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt. samer.abdelfattah99@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El-Haggar</LastName><ForeName>Sahar M</ForeName><Initials>SM</Initials><Identifier Source="ORCID">0000-0002-0882-7315</Identifier><AffiliationInfo><Affiliation>Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ali</LastName><ForeName>Abdel Moaty A</ForeName><Initials>AMA</Initials><Identifier Source="ORCID">0000-0002-4132-3530</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, Rehabilitation and Physical Medicine, Faculty of Medicine, Mansoura University, Mansoura, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mostafa</LastName><ForeName>Tarek M</ForeName><Initials>TM</Initials><Identifier Source="ORCID">0000-0003-1071-5416</Identifier><AffiliationInfo><Affiliation>Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05594680</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Inflammopharmacology</MedlineTA><NlmUniqueID>9112626</NlmUniqueID><ISSNLinking>0925-4692</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>N7Z035406B</RegistryNumber><NameOfSubstance UI="D000077407">Cilostazol</NameOfSubstance></Chemical><Chemical><RegistryNumber>YL5FZ2Y5U1</RegistryNumber><NameOfSubstance UI="D008727">Methotrexate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>E0399OZS9N</RegistryNumber><NameOfSubstance UI="D000242">Cyclic AMP</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077407" MajorTopicYN="Y">Cilostazol</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001172" MajorTopicYN="Y">Arthritis, Rheumatoid</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008727" MajorTopicYN="Y">Methotrexate</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="Y">Antirheumatic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000242" MajorTopicYN="N">Cyclic AMP</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017024" MajorTopicYN="N">Chemotherapy, Adjuvant</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cilostazol</Keyword><Keyword MajorTopicYN="N">DAS28-CRP</Keyword><Keyword MajorTopicYN="N">Methotrexate</Keyword><Keyword MajorTopicYN="N">RA</Keyword><Keyword MajorTopicYN="N">cAMP</Keyword></KeywordList><CoiStatement>Declarations. Conflict of interest: The authors have no relevant financial to declare. Ethical approval: Approval for the study was granted by the National Research Ethics Committee of Tanta University (Approval Code: 35930110\22) and the National Research Ethics Committee of Mansoura University (Approval Code: MS.22.10.2163). The procedures followed in this study are in accordance with the principles outlined in the Declaration of Helsinki, 1964. Consent to participate: Everyone involved in the research granted informed consent.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>1</Day><Hour>21</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>17</Day><Hour>17</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>16</Day><Hour>23</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>5</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40380042</ArticleId><ArticleId IdType="pmc">PMC12214005</ArticleId><ArticleId IdType="doi">10.1007/s10787-025-01782-2</ArticleId><ArticleId IdType="pii">10.1007/s10787-025-01782-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aflaki E, Sehatpour F, Banihashemi S (2024) Validation and Cultural Adaptation of Persian Version of Multidimensional Health Assessment Questionnaire in Rheumatoid Arthritis Patients. Mediterr J Rheumatol 35(1):83</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11082758</ArticleId><ArticleId IdType="pubmed">38736965</ArticleId></ArticleIdList></Reference><Reference><Citation>Angum F, Khan T, Kaler J, Siddiqui L, Hussain A (2020) The Prevalence of autoimmune disorders in women: a narrative review. Cureus. 10.7759/cureus.8094</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7292717</ArticleId><ArticleId IdType="pubmed">32542149</ArticleId></ArticleIdList></Reference><Reference><Citation>Antunes Andrade F, Goeldner Eibofner I, Pieczarka C, van Tong H, Sena L, Skare T et al (2021) Impact of VSIG4 gene polymorphisms on susceptibility and functional status of rheumatoid arthritis. Int J Immunogenet 48(3):260&#x2013;265</Citation><ArticleIdList><ArticleId IdType="pubmed">33645007</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell NK, Fitzgerald HK, Dunne A (2021) Regulation of inflammation by the antioxidant haem oxygenase 1. Nat Rev Immunol 21(7):411&#x2013;425</Citation><ArticleIdList><ArticleId IdType="pubmed">33514947</ArticleId></ArticleIdList></Reference><Reference><Citation>Carla F, Brito F De. (2020) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19. The COVID-19 resource centre is hosted on Elsevier Connect, the company &#x2019; s public news and information. (January)</Citation></Reference><Reference><Citation>Darwish NF, Tabra SAA, Baiomy NN, Mahmoud HA, Mariah RA, Hablas SA (2022) The implication of adenosine receptor expression in prediction of methotrexate clinical response in Egyptian rheumatoid arthritis patients. Egypt Rheumatol Rehabil. 10.1186/s43166-021-00107-9</Citation></Reference><Reference><Citation>de Oliveira LR, Lima GF, Mendes ABA, Autran LJ, de Assis Pereira NC, Braz&#xe3;o SC et al (2022) Cilostazol attenuates cardiac oxidative stress and inflammation in hypercholesterolemic rats. Naunyn Schmiedebergs Arch Pharmacol 395(7):789&#x2013;801</Citation><ArticleIdList><ArticleId IdType="pubmed">35384464</ArticleId></ArticleIdList></Reference><Reference><Citation>Edilova MI, Akram A, Abdul-Sater AA (2021) Innate immunity drives pathogenesis of rheumatoid arthritis. Biomed J 44(2):172&#x2013;182</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8178572</ArticleId><ArticleId IdType="pubmed">32798211</ArticleId></ArticleIdList></Reference><Reference><Citation>Elshazly SM, Elhassanny AEM, Mahmoud NM (2020) Cilostazol protects against acetic acid-induced colitis in rats: Possible role for cAMP/SIRT1 pathway. Eur J Pharmacol 881:173234</Citation><ArticleIdList><ArticleId IdType="pubmed">32497625</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang Y, Chen W, Li Z, Chen Y, Wu X, Zhu X et al (2022) The role of a key transcription factor PU.1 in autoimmune diseases. Front Immunol 13:1&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9557192</ArticleId><ArticleId IdType="pubmed">36248862</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Gonz&#xe1;lez CM, Baker J (2022) Treatment of early rheumatoid arthritis: Methotrexate and beyond. Curr Opin Pharmacol 64:102227</Citation><ArticleIdList><ArticleId IdType="pubmed">35453032</ArticleId></ArticleIdList></Reference><Reference><Citation>He YF, Huang Y, Mai CT, Pan H, Bin LH, Liu L et al (2020) The immunomodulatory role of PDEs inhibitors in immune cells: therapeutic implication in rheumatoid arthritis. Pharmacol Res 161:105134</Citation><ArticleIdList><ArticleId IdType="pubmed">32798648</ArticleId></ArticleIdList></Reference><Reference><Citation>Kherallah RY, Khawaja M, Olson M, Angiolillo D, Birnbaum Y (2022) Cilostazol: a review of basic mechanisms and clinical uses. Cardiovasc Drugs Ther. 36:777&#x2013;792. 10.1007/s10557-021-07187-x</Citation><ArticleIdList><ArticleId IdType="pubmed">33860901</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HY, Lee SW, Park SY, Baek SH, Lee CW, Hong KW et al (2012) Efficacy of concurrent administration of Cilostazol and methotrexate in rheumatoid arthritis: pharmacologic and clinical significance. Life Sci 91(7&#x2013;8):250&#x2013;257</Citation><ArticleIdList><ArticleId IdType="pubmed">22820172</ArticleId></ArticleIdList></Reference><Reference><Citation>Morovic-Vergles J, Culo MI, Gamulin S, Culo F (2008) Cyclic adenosine 5&#x2032;-monophosphate in synovial fluid of rheumatoid arthritis and osteoarthritis patients. Rheumatol Int 29:167&#x2013;171</Citation><ArticleIdList><ArticleId IdType="pubmed">18695981</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu Q, Gao J, Wang L, Liu J, Zhang L (2022) Regulation of differentiation and generation of osteoclasts in rheumatoid arthritis. Front Immunol 13(November):1&#x2013;17</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9716075</ArticleId><ArticleId IdType="pubmed">36466887</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacini ESA, Satori NA, Jackson EK, Godinho RO (2022) Extracellular cAMP-adenosine pathway signaling: a potential therapeutic target in chronic inflammatory airway diseases. Front Immunol 13:866097</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9038211</ArticleId><ArticleId IdType="pubmed">35479074</ArticleId></ArticleIdList></Reference><Reference><Citation>Pope JE, Choy EH (2021) C-reactive protein and implications in rheumatoid arthritis and associated comorbidities. Semin Arthritis Rheum 51(1):219&#x2013;229</Citation><ArticleIdList><ArticleId IdType="pubmed">33385862</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryter SW (2021) Heme oxgenase-1, a cardinal modulator of regulated cell death and inflammation. Cells 10(3):515</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7997353</ArticleId><ArticleId IdType="pubmed">33671004</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakamoto T, Ohashi W, Tomita K, Hattori K, Matsuda N, Hattori Y (2018) Anti-inflammatory properties of Cilostazol: Its interruption of DNA binding activity of NF-&#x3ba;B from the Toll-like receptor signaling pathways. Int Immunopharmacol 62(July):120&#x2013;131</Citation><ArticleIdList><ArticleId IdType="pubmed">30005227</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon DH, Glynn RJ, Karlson EW, Lu F, Corrigan C, Colls J et al (2020) Adverse effects of low-dose methotrexate: a randomized trial. Ann Intern Med 172(6):369&#x2013;380</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7229518</ArticleId><ArticleId IdType="pubmed">32066146</ArticleId></ArticleIdList></Reference><Reference><Citation>van Gestel AM, Anderson JJ, van Riel PL et al (1999) ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology. J Rheumatol 26(3):705&#x2013;711</Citation><ArticleIdList><ArticleId IdType="pubmed">10090187</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Zhou H, Liu L (2018) Side effects of methotrexate therapy for rheumatoid arthritis: a systematic review. Eur J Med Chem 158:502&#x2013;516</Citation><ArticleIdList><ArticleId IdType="pubmed">30243154</ArticleId></ArticleIdList></Reference><Reference><Citation>Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J et al (2009) Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythr. Ann Rheum Dis 68(6):954&#x2013;960</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674547</ArticleId><ArticleId IdType="pubmed">18490431</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie L, Li Z, Chen Z, Li M, Tao J (2023) ITGB1 alleviates osteoarthritis by inhibiting cartilage inflammation and apoptosis via activating cAMP pathway. J Orthop Surg Res 18(1):1&#x2013;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10634155</ArticleId><ArticleId IdType="pubmed">37941009</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T, Ma C, Zhang Z, Zhang H, Hu H (2021) NF-&#x3ba;B signaling in inflammation and cancer. MedComm 2(4):618&#x2013;653</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8706767</ArticleId><ArticleId IdType="pubmed">34977871</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>